Benchling has seen its business grow at a healthy lick since it launched in 2012 with a mission to improve the efficiency of the biopharma R&D process, but it looks li
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio